#1 Clinical Trials Search in Europe

LY3841136 SODIUM

Clinical trials are studying LY3841136 SODIUM, also called eloralintide, in people with obesity or overweight and related health problems. These studies look at whether it helps with body weight and, in some trials, sleep apnea or knee pain from osteoarthritis. Most trials are Phase 3 studies in adults.

Table of contents

Trial overview

The clinical trials in this article study LY3841136 SODIUM, which is also named eloralintide in the trial titles.[1][2][3][4][5]

All five listed studies are interventional trials, which means participants are assigned to receive a study treatment or a comparison treatment.[1][2][3][4][5]

The main research focus is body weight change in people with obesity or overweight, with some studies also looking at sleep apnea or knee pain from osteoarthritis.[1][2][3][4][5]

Who is being studied

The trials include people with obesity or overweight, which are the main target populations across the studies.[1][2][3][4][5]

One study includes participants with obstructive sleep apnea and obesity or overweight.[1]

One study includes participants with obesity or overweight and type 2 diabetes.[4]

One study includes participants with osteoarthritis knee pain and obesity or overweight.[3]

One study includes participants with persistent obesity who are treated with a weekly incretin, which is the wording used in the trial title.[5]

Trial goals and endpoints

The main goal in most studies is to show that LY3841136 SODIUM is better than placebo for percent change from baseline in body weight.[1][2][4][5]

In the study of obstructive sleep apnea, the trial also aims to show superiority over placebo for apnea-hypopnea index, which is a measure of how often breathing stops or becomes shallow during sleep.[1]

In the osteoarthritis study, the two main goals are body weight change and change in the WOMAC pain subscale score, which measures knee pain from osteoarthritis.[3]

Several studies measure body weight change at Week 64, showing that the trials are designed to follow results over a long period.[2][4][5]

Trial phases and status

All listed studies are in Phase 3, the stage where a treatment is tested in larger groups of people to confirm how well it works.[1][2][3][4][5]

Each trial is marked Authorised, which means the studies have been approved to move forward in the source data.[1][2][3][4][5]

The study sizes are fairly large, with enrollment ranging from 254 to 1035 participants.[1][2][3][4][5]

Study design and comparators

These studies compare LY3841136 SODIUM with a placebo, which is a look-alike treatment used to make the comparison fair.[1][2][3][4][5]

The trial titles show that LY3841136 SODIUM is given by subcutaneous use, meaning it is given under the skin.[1][2][3][4][5]

The source data do not provide detailed eligibility rules, so the safest summary is that these studies are for adults with the conditions named in each trial title.[1][2][3][4][5]

Key trials

ENLIGHTEN-1 studies participants with obesity or overweight without type 2 diabetes and measures percent change from baseline in body weight at Week 64.[2]

ENLIGHTEN-2 studies participants with obesity or overweight and type 2 diabetes, also with body weight change as the main outcome.[4]

ENLIGHTEN-3 studies participants with obstructive sleep apnea and obesity or overweight, and it looks at both body weight and apnea-hypopnea index.[1]

ENLIGHTEN-4 studies participants with osteoarthritis knee pain and obesity or overweight, and it measures body weight plus WOMAC pain score.[3]

ENLIGHTEN-6 studies participants with persistent obesity who are treated with a weekly incretin, and it focuses on body weight change.[5]

Patient-focused terms

Baseline means the starting point before treatment begins.[2][3][4][5]

Percent change from baseline means how much a value changes compared with the starting value, shown as a percent.[1][2][3][4][5]

Primary outcome means the main result the researchers want to measure in the trial.[1][2][3][4][5]

Enrollment means the number of participants planned for the study.[1][2][3][4][5]

Trial IDPhaseCondition studiedStatusEnrollment
2025-523769-11-00Phase 3Obstructive sleep apnea, obesity, overweightAuthorised800
2025-523657-34-00Phase 3Obesity, overweight without type 2 diabetesAuthorised254
2025-523768-19-00Phase 3Osteoarthritis knee pain, overweight or obesityAuthorised829
2025-523658-15-00Phase 3Obesity, overweight, type 2 diabetesAuthorised1035
2025-523659-73-00Phase 3Persistent obesity in people treated with a weekly incretinAuthorised950

FAQ

  • What is being studied in clinical trials of LY3841136 SODIUM? The trials are studying whether LY3841136 SODIUM helps people lose weight and improve related conditions. Some studies also measure sleep apnea severity or knee pain from osteoarthritis.
  • Who may be able to join these studies? The studies include adults with obesity or overweight. Some trials also include people with type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, or people who still have obesity while taking a weekly incretin.
  • What phase are these trials in? All of the listed studies are Phase 3 trials. Phase 3 means the treatment is being tested in larger groups of people to better understand its benefits and safety.
  • What conditions are being studied with LY3841136 SODIUM? The trials focus on obesity and overweight, with added groups for obstructive sleep apnea, type 2 diabetes, and osteoarthritis. One study looks at people with persistent obesity who are treated with a weekly incretin.
  • What are the main outcomes being measured? The main outcome in most trials is percent change in body weight from baseline. One trial also measures the apnea-hypopnea index, and another measures WOMAC pain score for knee osteoarthritis.

Ongoing Clinical Trials on LY3841136 SODIUM

  • A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Romania Spain

  • A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

    Recruiting

    3 1
    Investigated drugs:
    Belgium Germany Poland

Glossary

  • Phase 3: A late stage of clinical testing with larger numbers of participants. It helps show whether a treatment works better than a comparison treatment, often a placebo.
  • Placebo: A look-alike treatment that does not contain the study drug. It is used to compare results fairly.
  • Obesity: A medical condition where a person has too much body fat. It can raise the risk of other health problems.
  • Overweight: A condition where a person weighs more than what is considered healthy for their body size.
  • Type 2 diabetes: A long-term condition where the body does not use sugar in the blood properly.
  • Obstructive sleep apnea: A sleep disorder where breathing stops and starts during sleep because the airway becomes blocked.
  • Apnea-hypopnea index: A score that shows how often breathing stops or becomes shallow during sleep. A lower score usually means less severe sleep apnea.
  • WOMAC pain subscale: A questionnaire score used to measure knee pain and stiffness in people with osteoarthritis.
  • Baseline: The starting point before treatment begins. Changes are measured against this starting value.
  • Percent change in body weight: How much body weight changes compared with the starting weight, shown as a percent.

References

  1. https://clinicaltrials.gov/study/2025-523769-11-00
  2. https://clinicaltrials.gov/study/2025-523657-34-00
  3. https://clinicaltrials.gov/study/2025-523768-19-00
  4. https://clinicaltrials.gov/study/2025-523658-15-00
  5. https://clinicaltrials.gov/study/2025-523659-73-00